Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Reticulophagy regulator 2 (RETREG2) is a protein anchored in the endoplasmic reticulum (ER) membrane that functions as an ER-phagy receptor, helping regulate selective autophagy of the ER (termed "reticulophagy")[1][2][3][4]. RETREG2 is typically inactive under normal conditions but becomes activated following cellular stress, where it mediates ER fragmentation and facilitates sequestration of ER fragments into autophagosomes for lysosomal degradation through interaction with ATG8 family proteins[1][3][4]. This mechanism is important for maintenance of ER morphology, protein/collagen quality control, and adaptation to stress; dysfunction of RETREG2 has been linked to some forms of hereditary sensory and autonomic neuropathy[1][2][4][7]. Unlike classical drug targets such as receptors or enzymes, RETREG2 is not currently considered a therapeutic target and no drugs are known to directly modulate its function[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reticulophagy regulator 2 (RETREG2).